Galderma reported interim injectable-treatment findings in menopausal women. We assess the skin outcomes, evidence gaps and implications for care.
On October 22, 2026, Galderma reported interim findings of progressive improvements in hydration, skin-barrier function and skin quality in menopausal women treated with Restylane Skinboosters and Sculptra. The announcement appeared in the company’s earnings release, not a medical journal or clinical guideline.
The existing clinical distinction is between addressing a particular appearance concern and treating menopause itself. These findings concern injectable aesthetic treatments. The available reports do not establish them as general treatments for menopause symptoms or show that menopausal skin changes require a procedure.
The update is therefore about studying aesthetic treatments specifically in menopausal women rather than replacing an established menopause-care standard. That is a narrower development than a new treatment pathway for everyone experiencing skin changes.
Questions about how menopause-related skin changes are framed deserve attention without making every visible change a medical problem. Taking an appearance concern seriously does not require treating it as something that must be corrected.
The public accounts describe several outcomes and a comparison of treatment order. Keeping those findings separate helps prevent a broad phrase such as “better skin quality” from carrying more meaning than the reported measurements support.
Hydration, dermal thickness and patient satisfaction are different questions. A result for one should not be used as shorthand for all the others. The reported thickness percentages should therefore stay attached to dermal thickness rather than becoming a numerical claim about overall skin quality.
Patient satisfaction also deserves to be read in its own terms. It addresses participants’ assessment of their experience rather than serving as another measurement of skin thickness or barrier function. Both kinds of outcome can be relevant to aesthetic care without being interchangeable.
For a reader, the useful distinction is between a measured change and a personally meaningful outcome. A percentage may attract attention, but the practical question is what the change means for the concern a woman actually wants addressed. That interpretation belongs in a conversation about her goals rather than in a headline promising a particular result.
The limitations belong together because they determine how much weight the reported results can carry.
Galderma’s October 22 earnings release does not disclose the trial’s sample size, comparator or treatment schedule. It also omits information about randomization and blinding. It provides no numerical outcome data, statistical analyses or safety findings.
The release does not identify an investigator or point to a publication, registry entry or conference abstract. Aesthetics Journal supplies the investigator’s name and the treatment sequences, but its report does not provide a paper, protocol or registry identifier. It also does not provide the trial’s sample size, confidence intervals or adverse-event information.
The survey mentioned in the trade report needs particular care. Aesthetics Journal refers to a survey of 5,090 women in the UK, US, Brazil and China near its discussion of the treatment findings. Its wording does not clearly establish that those women were trial participants, so the survey count must not be presented as the clinical trial’s enrolment.
Galderma’s October 13 release also describes the eight-month study and the same dermal-thickness percentages. That is another company-issued account of the findings rather than independent validation. Repetition across company communications and trade coverage does not turn the underlying result into a replicated finding.
Taken together, these materials do not establish peer review or provide enough information to assess clinical significance. The percentages are not definitive estimates for routine practice or proof that one sequence is superior. The absence of published safety results is also not evidence that no adverse events occurred.
The October 22 announcement was part of a business update. Galderma reported nine-month 2026 net sales of $4.765 billion, including $2.174 billion in Injectable Aesthetics.
Those figures explain the commercial setting in which the research was highlighted. They do not validate a skin outcome or establish which women might find an aesthetic procedure worthwhile. Sales performance and clinical evidence answer different questions.
Company support does not, by itself, settle whether a finding is useful. The editorial task is to keep the reported observation separate from its commercial presentation. Here, that means attributing the improvements to Galderma’s interim account rather than describing them as an established treatment benefit for menopausal women.
For someone interested in aesthetic treatment, this research provides topics for discussion rather than a treatment sequence to follow. A qualified clinician can connect the evidence with the individual concern and the decision about whether any procedure is appropriate.
Useful questions arising from the report include:
These questions leave room for appearance and confidence to matter without making treatment obligatory. A woman does not need to dismiss a skin concern as trivial, nor does interest in that concern commit her to an intervention.
The same distinction between a personal goal and a treatment claim is useful when reading about off-label oestrogen use on the face. That is a separate topic from this injectable study and should be assessed on its own evidence rather than folded into a single category of “menopause skincare.”
For now, this research is more likely to sharpen questions in aesthetic consultations and future studies than to justify a new menopause-care protocol.
Preliminary injectable findings can turn into pressure to correct menopausal skin when commercial messaging outruns the evidence. Refemina’s research-led coverage gives women navigating midlife a clearer account of skin and hair claims, with attention to uncertainty and confidence rather than anti-aging promises or the idea that every visible change needs an intervention.
Follow Refemina for research-led insights on menopause, strength, metabolism, nutrition, skin, intimacy and confidence through midlife. New articles turn complex topics into clear, useful context.
Keep learning about the changes that shape energy, strength, confidence and wellbeing through midlife.
Explore Resources